<DOC>
	<DOCNO>NCT00862563</DOCNO>
	<brief_summary>This double-blind , placebo-controlled , parallel group design study 4 treatment group ; levetiracetam , zonisamide , topiramate , placebo control . Subjects receive study medication 14 week . Potential subject initially screen interest study participation alcohol consumption level determine basic eligibility telephone , person . Individuals meet telephone screen criterion schedule clinic appointment obtain informed consent conduct screen assessment . Subjects report average drink per day within guideline safe level alcohol consumption ( i.e . 2 drinks/ day male ; 1 drink/day females-HHS standard ) two week prior screen exclude . Subjects meet screen criterion schedule second randomization visit . During visit baseline assessment obtain . Eligible subject randomize treatment group provide first week 's study medication . The goal directly compare efficacy tolerability two novel anticonvulsant , zonisamide levetiracetam , placebo , use topiramate , extensive evidence support efficacy alcoholism , positive control group . We believe first direct comparison agent alcoholism , result provide information efficacy safety medication .</brief_summary>
	<brief_title>Interdisciplinary Study Two Novel Anticonvulsants Alcoholism</brief_title>
	<detailed_description>This double-blind , placebo-controlled , parallel group design study 4 treatment group ; levetiracetam , zonisamide , topiramate , placebo control . This study evaluate effect zonisamide ( 400 mg per day ) alcohol consumption neurotoxic effect subject AUDS . A double-blind placebo-controlled clinical trial conduct use two comparator anticonvulsant drug , topiramate ( 300 mg daily ) levetiracetam ( 2000 mg/day ) , impair cognition . Topiramate use active control study . Study medication administer 14 week , include 2-week taper period . Target maintenance dos study medication administer subject study week 8-12 . Dosage reduction make need allow subject tolerate study medication . During medication taper phase study ( Weeks 13-14 ) Principal Investigator allow flexibility titration schedule instance subject experience event consistent withdrawal , example anxiety . Neurotoxicity study drug assess use neuropsychological test AB-Neurotoxicity scale . An adaptive randomization procedure sex heavy drinking history factor assignment subject treatment group . do use sex heavy drinking . Very heavy drinking define male subject consume 10 standard drink per day female subject consume 8 standard drink per day 40 percent day screen TLFB . Medication adherence facilitate use Brief Behavioral Compliance Enhancement Treatment . It brief , standardized therapy emphasize medication adherence crucial improvement drink behavior . Subject assessment include , limit following : 1 ) TLFB , 2 ) Adverse Events ( AEs ) assessment ,3 ) A-B Neurotoxicity Scale ( week 1,4,8,12,15 ) , 4 ) Neuropsychological battery Assessments- include Controlled Word Association Test ( COWAT ) Digit Spatial Span portion Wechsler Memory Scale- 3rd ( week 1,12 ) .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>To admit study candidate must meet following criterion : 1 . DSMIVTR Diagnosis Alcohol Dependence . 2 . A minimal level average 28 standard drink per week woman 35 drink per week men baseline 28 day consecutive period prior screen session 90 day time line followback . 3 . Male Female 21 65 year age . 4 . Able provide inform consent comprehend study procedure . 5 . Negative urine toxicological screen opioids , cocaine , amphetamine , methamphetamine , benzodiazepine . The test may repeat opioids benzodiazepine show medically prescribe acute disorder . The urine test may also repeat Investigator deem necessary . 6 . A score &gt; 8 Alcohol Use Disorder Identification Test ( AUDIT ) screening . 7 . Must suitable outpatient management alcoholism . 8 . Express desire stop drinking reduce alcohol consumption . 9 . Provide contact information alternate contact staff call case miss appointment . 10 . Women must postmenopausal least one year , surgically sterile , use effective method birth control . 11 . Must able take oral medication , adhere regimen willing return follow visit . Subjects meet follow criterion exclude study : 1 . Dependent DSM IVTR drug substance ethanol , nicotine , caffeine . 2 . DSM IVTR diagnosis current Axis I diagnosis alcohol dependence , nicotine dependence , caffeine dependence opinion study physician might require intervention either pharmacological nonpharmacological therapy interfere course study . 3 . Receiving inpatient treatment alcohol dependence , alcohol detoxification , within 4 week prior enrollment study . 4 . Subjects score 10 great Clinical Institute Withdrawal Assessment AlcoholRevised first second visit . 5 . Being treated acamprosate , disulfiram naltrexone within two week prior randomization : 6 . Currently treat follow medication : ) antipsychotic agent . b ) antimanic anticonvulsant agent . c ) sedative hypnotic . ) chronic opioid treatment . e ) psychomotor stimulant amphetamine derivative , methylphenidate 7 . Subjects legally mandate participate alcohol treatment program . 8 . Use medication know inhibit induce cytochrome P450 3A4 enzyme . 9 . Subjects attempt suicide suicidal ideation within 30 day first visit . 10 . Subjects renal disease history kidney stone . 11 . Subjects AST ALT &gt; 3 time upper limit normal range screening . 12 . History significant neurological disorder . 13 . Subjects pregnant ( assessed serum HCG ) lactating . 14 . Subjects know clinically significant medical condition opinion study physician would preclude administration study medication limit participation clinical trial . 15 . Subjects history treatment levetiracetam , topiramate zonisamide . 16 . Score 25 less Folstein Mini Mental examination . 17 . History anticonvulsantinduced rash . 18 . Taking drug contain `` sulfa '' moiety , sulfonamide , sulfonylurea , carbonic anhydrase inhibitor , thiazide , loop diuretic ( except ethacrynic acid ) . 19 . During 2 week prior screen subject report average drink per day within guideline safe level alcohol consumption ( i.e . 2 drinks/ day male ; 1 drink/day femalesHHS standard ) exclude . 20 . Subjects sulfa allergy .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Alcoholism</keyword>
	<keyword>Alcohol Dependence</keyword>
	<keyword>Alcohol Abuse</keyword>
	<keyword>Substance Abuse</keyword>
	<keyword>Alcoholic Intoxication</keyword>
</DOC>